People News: Biogen Idec and Nektar Therapeutics

Caroline Dorsa, a former Merck exec, was appointed to Biogen Idec's board of directors. Dorsa, previously SVP global human health, strategy and integration at Merck, is currently EVP and chief financial officer at Public Service Enterprise Group. Her appointment, to fill a vacancy, comes days after the announcement that president and CEO James Mullen would retire from Biogen Idec in June.

Stephen K. Doberstein, PhD was named SVP, chief scientific officer at Nektar Therapeutics, reporting to CEO Howard Robin. Dr. Doberstein, 50, joins Nektar from Xoma, where he was VP research, responsible for directing discovery and development of drug candidates.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.